Q32 Bio (NASDAQ:QTTB) CFO Sells $18,017.45 in Stock

Q32 Bio Inc. (NASDAQ:QTTB) CFO Lee Kalowski sold 3,995 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $4.51, for a total transaction of $18,017.45. Following the sale, the chief financial officer directly owned 35,943 shares of the company’s stock, valued at approximately $162,102.93. The trade was a 10.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Lee Kalowski also recently made the following trade(s):

• On Tuesday, December 2nd, Lee Kalowski sold 9,072 shares of Q32 Bio stock. The shares were sold at an average price of $3.46, for a total value of $31,389.12.

Q32 Bio Price Performance

NASDAQ QTTB opened at $4.56 on Monday. The company has a fifty day moving average price of $3.81 and a 200-day moving average price of $2.91. The firm has a market cap of $56.09 million, a price-to-earnings ratio of -1.33 and a beta of 0.14. Q32 Bio Inc. has a 1 year low of $1.35 and a 1 year high of $6.37.

Wall Street Analyst Weigh In

A number of brokerages recently commented on QTTB. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Q32 Bio in a research report on Friday, January 9th. HC Wainwright assumed coverage on Q32 Bio in a research report on Wednesday, February 25th. They set a “buy” rating and a $13.00 target price for the company. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $14.00.

Institutional Trading of Q32 Bio

A number of large investors have recently bought and sold shares of QTTB. Marshall Wace LLP bought a new stake in shares of Q32 Bio in the second quarter valued at $25,000. Acadian Asset Management LLC bought a new position in shares of Q32 Bio during the 1st quarter worth $50,000. Two Sigma Investments LP purchased a new stake in Q32 Bio in the 3rd quarter worth about $62,000. ADAR1 Capital Management LLC bought a new stake in Q32 Bio in the 4th quarter valued at about $66,000. Finally, AQR Capital Management LLC bought a new stake in Q32 Bio in the 1st quarter valued at about $68,000. 31.32% of the stock is owned by hedge funds and other institutional investors.

More Q32 Bio News

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $13 price target, providing a long‑term constructive view that can support upside versus current levels. HC Wainwright Begins Coverage on Q32 Bio
• Neutral Sentiment: HC Wainwright published a multi‑year forecast showing improving EPS over time and an eventual transition to modest profitability in FY2030 (EPS $0.11), which is a positive directional signal but depends on successful clinical and commercial execution.
• Negative Sentiment: The analyst model shows substantial near‑term losses: Q4 2025 EPS of ($0.63) and FY2025–FY2028 EPS ranging from about ($2.91) to ($2.19). These projected deficits increase financing and execution risk and likely weigh on short‑term investor sentiment.
• Negative Sentiment: Consensus full‑year earnings remain deeply negative (current consensus ~($12.32) per share), indicating the market and other analysts expect much larger near‑term losses than HC Wainwright’s more optimistic runway—this divergence may temper the impact of the Buy rating.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.